sign in · help · news · about ·

BibSonomy :: user :: kanefendt ::

tag user group author concept BibTeX key search:all search:kanefendt

The blue social bookmark and publication sharing system.

>
|
<

bookmarks

bookmarks per page: 5 10 20 50 100

RSS BibTeX RDF more

publications

(23)

<< < 1 | 2 > >>

Sunitinib efficacy against advanced renal cell carcinoma
R. J. Motzer, M. D. Michaelson, J. Rosenberg, R. M. Bukowski, B. D. Curti, D. J. George, G. R. Hudes, B. G. Redman, K. A. Margolin, and G. Wilding J.Urol. 178(5):1883-1887 (2007)
to & Administration Adult Aged Agents Antineoplastic Carcinoma Cell Disease Disease-Free Female Follow-Up Humans Indoles Kidney Laboratories Male Method Middle Neoplasm Neoplasms Oral Outcome Progression Pyrroles Rate Renal Research Retrospective Single-Blind Staging States Studies Survival Treatment Tyrosine United administration dosage drug epidemiology methods mortality pathology response therapy by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy
J. M. Ebos, C. R. Lee, J. G. Christensen, A. J. Mutsaers, and R. S. Kerbel Proc.Natl.Acad.Sci.U.S.A 104(43):17069-17074 (2007)
to & A Administration Agents Angiogenesis Animals Antineoplastic Antitumor Assays Blood Cell Dose-Response Drug Endothelial Factor Female Growth Humans Hypoxia Indoles Inducing Line Mice Model Neoplasms Organ Outcome Placenta Pregnancy Proteins Pyrroles RANGE Receptor-2 Relationship Research Schedule Scid Specificity Treatment Tumor Tyrosine Vascular Xenograft administration blood dosage drug effects metabolism pathology pharmacology protein response therapy toxicity by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition
H. M. Verheul, and H. M. Pinedo Nat.Rev.Cancer 7(6):475-485 (2007)
to & A Administration Agents Angiogenesis Antineoplastic Biological Blood Clinical Coagulation Drug Endothelial Factor Function Growth Humans Hypertension Inhibitors Left Models Neoplasm Platelets Research Resistance Schedule Signal Thrombosis Topic Transduction Trials Vascular Ventricular administration adverse antagonists as chemically dosage drug effects etiology induced inhibitors physiology toxicity by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan
B. Vincenzi, D. Santini, A. Russo, M. Gavasci, F. Battistoni, G. Dicuonzo, L. Rocci, V. M. Rosaria, N. Gebbia, and G. Tonini Pharmacogenomics. 8(4):319-327 (2007)
to & A Adult Aged Antibodies Antineoplastic Biological Camptothecin Chemotherapy Colorectal Combined Disease Endothelial Factor Female Growth Humans Male Markers Medical Middle Monoclonal Neoplasms Oncology Outcome Progression Prospective Protocols Rate Studies Survival Treatment Tumor Vascular administration analogs antagonists blood derivatives dosage drug inhibitors methods mortality response therapeutic therapy trends use by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays
C. T. Viswanathan, S. Bansal, B. Booth, A. J. DeStefano, M. J. Rose, J. Sailstad, V. P. Shah, J. P. Skelly, P. G. Swann, and R. Weiner Pharm.Res. 24(10):1962-1973 (2007)
to & Administration Animals Artifacts Assay Binding Biological Body Calibration Chemistry Chromatography Control Documentation Drug Fluids Food Government Guidelines Humans Macromolecular Pharmaceutical Quality Radioligand Reference Regulation Reproducibility Research Results Species Specificity Stability Standards States Substances Technology Topic United and as jurisprudence legislation methods of standards by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane
H. J. Burstein, A. D. Elias, H. S. Rugo, M. A. Cobleigh, A. C. Wolff, P. D. Eisenberg, M. Lehman, B. J. Adams, C. L. Bello, S. E. Deprimo, C. M. Baum, and K. D. Miller J Clin Oncol 26(11):1810-1816 (2008)
to & Administration Adult Aged Agents Anthracyclines Antineoplastic Biological Breast Bridged Carcinoma Chemotherapy Combined Compounds Diseases Drug Fatigue Female Gastrointestinal Growth Hematologic Humans Indoles Inflammation Kinase Kinases Markers Middle Neoplasms Oral Plasma Protein-Tyrosine Protocols Pyrroles Rate Schedule Survival Taxoids Tumor Tyrosine administration adverse analysis antagonists blood chemically classification dosage drug effects induced inhibitors methods mortality response secondary therapeutic therapy use by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors
F. A. Eskens, N. Steeghs, J. Verweij, J. L. Bloem, O. Christensen, Doorn L. van, J. Ouwerkerk, M. J. Jonge, J. W. Nortier, J. Kraetzschmar, P. Rajagopalan, and H. Gelderblom J.Clin.Oncol. 27(25):4169-4176 (2009)
to & A Administration Adolescent Adult Aged Angiogenesis Biological Contrast Dose Dose-Response Drug Endothelial Factor Factors Fatigue Female Growth Human Humans Hypertension Imaging Inhibitors Kinase Magnetic Male Markers Maximum Media Medical Metastasis Middle Neoplasm Neoplasms Oncology Oral Outcome Pharmacokinetics Plasma Platelet-Derived Protein Proteins Proto-Oncogene Pyridazines Pyridines Receptor Receptor-2 Receptor-3 Relationship Research Resonance Safety Schedule Time Tolerated Treatment Tumor Tyrosine Vascular Young administration adverse antagonists beta blood c-kit diagnostic dosage drug effects enzymology inhibitors methods pathology protein response supply therapy toxicity use by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Antiangiogenesis research is booming, as questions and studies proliferate
V. Brower J.Natl.Cancer Inst. 101(11):780-781 (2009)
to & Administration Analysis Angiogenesis Antibodies Antineoplastic Biological Chemotherapy Colorectal Combined Controlled Drug Humans Inhibitors Markers Monoclonal Neoplasms Pericytes Protocols Randomized Research Schedule Survival Topic Trials Tumor administration analysis as blood dosage drug effects mortality supply therapeutic therapy use by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100
B. P. Schneider, M. Wang, M. Radovich, G. W. Sledge, S. Badve, A. Thor, D. A. Flockhart, B. Hancock, N. Davidson, J. Gralow, M. Dickler, E. A. Perez, M. Cobleigh, T. Shenkier, S. Edgerton, and K. D. Miller J.Clin.Oncol. 26(28):4672-4678 (2008)
to & A Antibodies Antineoplastic Breast Chemotherapy Combined Dna Endothelial Factor Female Genotype Growth Haplotypes Hazards Humans Hypertension Models Monoclonal Neoplasms Nonparametric Nucleotide Paclitaxel Polymorphism Proportional Protocols Rate Receptor-2 Research Retrospective Single Statistics Studies Survival Vascular administration dosage drug genetics methods pathology therapeutic therapy toxicity use by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Phase I dose escalation study of telatinib BAY 57-9352 in patients with advanced solid tumours
D. Strumberg, B. Schultheis, I. A. Adamietz, O. Christensen, M. Buechert, J. Kraetzschmar, P. Rajagopalan, M. Ludwig, A. Frost, S. Steinbild, M. E. Scheulen, and K. Mross Br.J.Cancer 99(10):1579-1585 (2008)
to & 80 Adult Aged Agents Angiogenesis Antineoplastic Carcinoma Dose Female Growth Humans Hypertension Imaging Inhibitors Magnetic Male Maximum Medical Middle Neoplasms Oncology Plasma Pyridazines Pyridines RANGE Resonance Tolerated Tyrosine administration and blood dosage drug over response therapy by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Soluble form of vascular cell adhesion molecule 1 induces migration and proliferation of vascular smooth muscle cells
H. M. Lee, H. J. Kim, K. J. Won, W. S. Choi, S. H. Park, H. Song, P. J. Park, T. K. Park, C. K. Lee, and B. Kim J.Vasc.Res. 45(3):259-268 (2008)
to & Adhesion Animals Aorta Cell Chemistry Cultured Dose-Response Drug Growth Hypertension Inbred Male Molecule-1 Movement Muscle Myocytes Phosphorylation Proliferation Rats Relationship Research SHR Signal Smooth Solubility Sprague-Dawley Transduction Tyrosine Vascular WKY administration cells cytology development dosage drug effects growth methods pathology pharmacology physiopathology response by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Platelet: transporter of vascular endothelial growth factor
H. M. Verheul, K. Hoekman, Bakker S. Luykx de, C. A. Eekman, C. C. Folman, H. J. Broxterman, and H. M. Pinedo Clin.Cancer Res. 3(12 Pt 1):2187-2190 (1997)
to & A Activation Antineoplastic Blood Breast Burden Chemotherapy Colony-Stimulating Combined Cyclophosphamide Doxorubicin Endothelial Factor Factors Female Granulocyte-Macrophage Growth Healing Humans Lymphokines Medical Neoplasms Oncology Platelet Platelets Protocols Reference Research Tumor Values Vascular Wound administration adverse blood dosage drug effects physiology therapeutic therapy use by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Overview of monoclonal antibodies and small molecules targeting the epidermal growth factor receptor pathway in colorectal cancer
L. C. Snyder, I. Astsaturov, and L. M. Weiner Clin.Colorectal Cancer (2005)
to & Administration Amplification Antibodies Approval Binding Colorectal Drug Epidermal Exanthema Factor Food Gene Growth Humans IgG Ligands Medical Molecular Monoclonal Neoplasms Oncology Phosphorylation Prognosis Receptor Receptors Signal Sites States Transduction Tyrosine United Weight and antagonists biosynthesis cells chemically drug induced inhibitors pharmacology physiology physiopathology response therapeutic therapy use by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Increased plasma vascular endothelial growth factor VEGF as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies
G. Bocci, S. Man, S. K. Green, G. Francia, J. M. Ebos, J. M. Du Manoir, A. Weinerman, U. Emmenegger, L. Ma, P. Thorpe, A. Davidoff, J. Huber, D. J. Hicklin, and R. S. Kerbel Cancer Res. 64(18):6616-6625 (2004)
to & A Adenocarcinoma Administration Angiogenesis Animals Antibodies Antineoplastic Biological Blood Cell Chemotherapy Colorectal Combined Drug Endothelial Factor Growth Human Humans Inhibitors Line Male Markers Messenger Mice Modality Monoclonal Neoplasms Neovascularization Nude Pathologic Platelets Prostatic Protocols RNA Receptor-2 Research Schedule Scid Therapy Tumor Vascular administration biosynthesis blood dosage genetics immunology metabolism protein supply therapy by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)

<< < 1 | 2 > >>publications per page: 5 10 20 50 100

a gripper